<DOC>
	<DOCNO>NCT00157079</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Immune Globulin Intravenous ( Human ) , 10 % ( IGIV 10 % ) subject primary immunodeficiency disorder .</brief_summary>
	<brief_title>Safety Efficacy Study 10 % Intravenous Immune Globulin Solution Subjects With Primary Immunodeficiency Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Written inform consent obtain either subject subject 's legally acceptable representative prior studyrelated procedure study product administration Diagnosis PID disorder define World Health Organization criterion subject receive regimen IGIV infusion every 21 28 day period least 4 month prestudy dose 300600 mg/kg body weight Subjects &gt; 24 month age A negative serum pregnancy test female subject childbearing potential . Subjects seropositive enrollment one following : hepatitis B surface antigen ( HBsAg ) , antibodies hepatitis C virus ( HCV ) , antibodies human immunodeficiency virus ( HIV ) Types 1 2 Subjects level alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 time upper limit normal test laboratory . An AST &gt; 2.5 time upper limit normal allowable , ALT exceed upper limit reference range test laboratory Subjects neutropenia ( define ANC &gt; = 1,000/mm3 ) Subjects serum creatinine level great two time upper limit normal age gender Subjects malignancy history malignancy Subjects receive blood blood product exposure IGIV and/or immune serum globulin ( ISG ) preparation within 6 month prior study entry Subjects ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow IGIV and/or ISG infusion Subjects selective complete IgA deficiency Subjects moderate level antiIgA antibody ( &gt; 150 ) , subject low antiIgA antibody naive IGIV treatment . ( Subjects low level IgA antibody , investigator know tolerate IgA contain IGIV preparation past , may include investigator comfortable ) Subjects receive antibiotic therapy treatment infection within 30 day prior enrollment Subjects receive prophylactic antibiotic part care regimen Subjects participate another clinical study involve investigational product device within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>PID</keyword>
	<keyword>Immune Thrombocytopenic Purpura ( ITP )</keyword>
	<keyword>Kawasaki syndrome</keyword>
	<keyword>Immunodeficiency</keyword>
</DOC>